5 Drug Hopefuls That Are Going to Change Your Life: Part 1Motley FoolIt currently has a partnership with Abbott Labs (NYSE: ABT ) and is in the middle of a late-stage MS trial for daclizumab, a subcutaneous injection for relapsing and remitting MS . Mo…
SEP : un engagement, des résultats !JIM.frIl nous a aussi informé de l'existence d'autres produits en cours d'investigation dans la sclérose en plaques : un anticorps monoclonal anti-CD 25 (daclizumab), un interféron pegylé et un anti-…
Avonex Share of First-Line Therapy Among Multiple Sclerosis Patients has …MarketWatch (press release)Patient profiles for the eight DMAs in late clinical development (Aubagio, BG-12, alemtuzumab, PEG-Avonex, Copaxone 40mg 3x weekly, daclizumab, laqui…
US Patents Awarded to Inventors in Maryland (Nov. 5)Equities.comIn particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other…
SEP : l'alemtuzumab pourrait bientôt jouer dans la même cour que le TysabriMedscape FranceD'autres anticorps monoclonaux sont actuellement en développement à un stade moins avancé, au rang desquels l'ocrelizumab, et le daclizumab. Mais…
Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third QuarterBusiness Wire (press release)Approved and investigational therapies in Biogen Idec's MS franchise presented at the conference included BG-12, daclizumab-HYP, anti-LINGO, TY…
Biogen Idec Management Discusses Q3 2012 Results – Earnings Call TranscriptSeeking AlphaIn a second latebreaking presentation at ECTRIMS, we highlighted primary efficacy results from SELECTION, the one-year extension study of SELECT, the first registra…
Multiple sclerosis DMT approvals "to double by 2012"Pharma Times… will likely constrain the adoption of these potentially high-risk/high-reward therapies by a generally conservative neurologist prescriber base, and forecasts that, together …
BIIB's BG-12 Review Period Extended – Analyst BlogNASDAQMeanwhile, Biogen and partner Abbott Labs ( ABT ) moved another MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010, with results due in 2014. Daclizumab is being e…
BIIB's BG-12 Review Period ExtendedZacks.comMeanwhile, Biogen and partner Abbott Labs (ABT – Analyst Report) moved another MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010, with results due in 2014. Daclizumab is bein…